收费全文 | 170400篇 |
免费 | 17284篇 |
国内免费 | 10270篇 |
耳鼻咽喉 | 1317篇 |
儿科学 | 2157篇 |
妇产科学 | 1814篇 |
基础医学 | 23890篇 |
口腔科学 | 3102篇 |
临床医学 | 20953篇 |
内科学 | 23091篇 |
皮肤病学 | 1891篇 |
神经病学 | 8055篇 |
特种医学 | 5984篇 |
外国民族医学 | 77篇 |
外科学 | 16167篇 |
综合类 | 28957篇 |
现状与发展 | 37篇 |
一般理论 | 15篇 |
预防医学 | 12594篇 |
眼科学 | 4180篇 |
药学 | 19966篇 |
155篇 | |
中国医学 | 10488篇 |
肿瘤学 | 13064篇 |
2024年 | 777篇 |
2023年 | 2872篇 |
2022年 | 7289篇 |
2021年 | 9156篇 |
2020年 | 6772篇 |
2019年 | 5727篇 |
2018年 | 6005篇 |
2017年 | 5629篇 |
2016年 | 5220篇 |
2015年 | 7672篇 |
2014年 | 9389篇 |
2013年 | 9148篇 |
2012年 | 12897篇 |
2011年 | 13597篇 |
2010年 | 9558篇 |
2009年 | 7687篇 |
2008年 | 9165篇 |
2007年 | 9141篇 |
2006年 | 8320篇 |
2005年 | 7427篇 |
2004年 | 5726篇 |
2003年 | 5695篇 |
2002年 | 4797篇 |
2001年 | 4005篇 |
2000年 | 3360篇 |
1999年 | 2946篇 |
1998年 | 1848篇 |
1997年 | 1952篇 |
1996年 | 1377篇 |
1995年 | 1295篇 |
1994年 | 1171篇 |
1993年 | 817篇 |
1992年 | 1056篇 |
1991年 | 945篇 |
1990年 | 871篇 |
1989年 | 774篇 |
1988年 | 702篇 |
1987年 | 603篇 |
1986年 | 557篇 |
1985年 | 444篇 |
1984年 | 387篇 |
1983年 | 313篇 |
1982年 | 274篇 |
1981年 | 234篇 |
1980年 | 199篇 |
1979年 | 214篇 |
1978年 | 198篇 |
1977年 | 215篇 |
1976年 | 194篇 |
1974年 | 161篇 |
Research design and methods: A sample of 1139 reports received by the Shaanxi ADR Monitoring Center from January 2015 to December 2017 was selected. ADR report quality was evaluated using an ADR report quality evaluation system.
Results: None of the reports were rated as excellent and 1.40% (n = 16) as good. Report quality was better for new and serious reports than for general reports. Medical institutions generated higher quality reports than pharmaceutical manufacturers. Nurses generated higher quality reports than doctors, pharmacists, and other professionals. Reporters of different occupations showed significant differences in the quality of the indicators Reporting time limit, Intervention ADR time, ADR termination time, ADR intervention measures, Original disease, and Cause of medication (P = 0.000).
Conclusions: The ADR data quality was poor in western China, and of lower quality than reported data from previous research in other regions. Improvements in the quality and availability of ADR reports are urgently needed. 相似文献
Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge.
Results: Overall, mortality (16.2% vs. 5.3%; p?<?.01), median hospital LOS (42.0 vs. 26.0 days; p?<?.01) and median total costs ($173,144 vs. $98,982; p?<?.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups.
Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT. 相似文献